Compass TherapeuticsCMPX
CMPX
About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Employees: 35
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
118% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
15% more funds holding
Funds holding: 79 [Q3] → 91 (+12) [Q4]
6.66% more ownership
Funds ownership: 67.0% [Q3] → 73.67% (+6.66%) [Q4]
13% less capital invested
Capital invested by funds: $170M [Q3] → $147M (-$22.6M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
243%
upside
Avg. target
$15.67
795%
upside
High target
$32
1,729%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target | 1,271%upside $24 | Buy Maintained | 4 Apr 2025 |
Guggenheim Michael Schmidt 27% 1-year accuracy 10 / 37 met price target | 586%upside $12 | Buy Reiterated | 2 Apr 2025 |
Leerink Partners Andrew Berens 20% 1-year accuracy 1 / 5 met price target | 243%upside $6 | Outperform Upgraded | 2 Apr 2025 |
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 1,729%upside $32 | Buy Maintained | 1 Apr 2025 |
Piper Sandler Biren Amin 20% 1-year accuracy 5 / 25 met price target | 586%upside $12 | Overweight Initiated | 19 Feb 2025 |
Financial journalist opinion
Based on 3 articles about CMPX published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.
Neutral
GlobeNewsWire
2 weeks ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Neutral
GlobeNewsWire
1 month ago
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Positive
Zacks Investment Research
2 months ago
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
MarketBeat
2 months ago
Top 3 High-Momentum Companies Analysts Are Still Bullish On
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing.
Positive
Zacks Investment Research
2 months ago
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
Positive
Zacks Investment Research
4 months ago
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
4 months ago
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
Neutral
Seeking Alpha
4 months ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors.
Charts implemented using Lightweight Charts™